Johnson & Johnson’s $5.5 Billion Talc Deal Aims to End 76,000 Cancer Claims
Johnson & Johnson has agreed to a $5.5 billion settlement that will address over 76,000 cases claiming that its talc-based products caused ovarian cancer, a major step toward concluding a decade-long court struggle. The deal covers most outstanding claims, with payments starting in 2027.